Item 8.01 Other Events.

On April 28, 2021, Timber Pharmaceuticals, Inc., a Delaware corporation (the "Company"), announced that the Japanese Patent Office has decided to grant a patent (No. 2018-542677) for its lead asset, TMB-001, the Company's topical pharmaceutical composition of isotretinoin that is currently being evaluated for the treatment of moderate to severe subtypes of congenital ichthyosis.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.



Exhibit No.                            Exhibit

  99.1          Press Release issued by the Company on April 28, 2021.

© Edgar Online, source Glimpses